Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
S. Matthijs Boekholdt(Amsterdam Neuroscience), John J.P. Kastelein(QRx Pharma (United States)), Andrew Tonkin(Monash University), Michael Clearfield, Aeilko H. Zwinderman(Amsterdam Neuroscience), John R. Downs, Paul J. Nestel(Baker Heart and Diabetes Institute), G. A. Hitman, Antonio M. Gotto(Cornell University), Benoît J. Arsenault(Emory University), Samia Mora(Brigham and Women's Hospital), Paul N. Durrington(University of Manchester), Paul M. Ridker(Herlev Hospital), R. John Simes, John C. LaRosa(SUNY Downstate Health Sciences University), K.M.A. Welch, Helen M. Colhoun(Edinburgh Cancer Research), Terje R. Pedersen(University of Oslo), David A. DeMicco(Pfizer (United States))
Cited by 800
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k